Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when XENE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsXenon Pharmaceuticals files routine annual meeting notice with Canadian regulators
Filed March 13, 2026 · Period ending March 13, 2026 · ~1 min read
Key Changes
-
low
Company announced details for its 2026 annual shareholder meeting through a Canadian SEDAR+ filing, including meeting date and record date information.
Item 8.01 verify on EDGAR → -
low
This 8-K is a procedural cross-reference to a Canadian regulatory filing with no material business disclosures or operational updates.
8-K: SEDAR+ Filing verify on EDGAR →
Summary
Xenon Pharmaceuticals filed a routine 8-K on March 13, 2026, to disclose that it submitted annual meeting information to SEDAR+, Canada's electronic securities filing system. The filing announces administrative details for the company's 2026 annual shareholder meeting, including the meeting date and record date for determining which shareholders are eligible to vote. This is a standard procedural disclosure with no impact on the company's business operations, financial condition, or drug development pipeline.
Retail investors should view this as routine corporate housekeeping required for companies listed in both the U.S. and Canada. Shareholders should watch for the actual proxy statement, which will contain details about board nominees, executive compensation, and any shareholder proposals up for vote at the annual meeting.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
On March 13, 2026, Xenon Pharmaceuticals Inc. announced the meeting, record date and certain other information relating to its 2026 annual meeting of shareholders pursuant to a filing submitted to the System for Electronic Document Analysis and Retrieval in Canada.
The company disclosed administrative details for its upcoming 2026 annual shareholder meeting through a Canadian regulatory filing. This is a routine procedural disclosure with no material business impact.
Event · Item 9.01 — Financial Statements and Exhibits
Xenon Pharmaceuticals filed a routine 8-K furnishing a SEDAR+ filing with no material business disclosures.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
SEDAR+ filing submitted March 13, 2026.
The company furnished a SEDAR+ filing dated March 13, 2026. SEDAR+ is the Canadian securities filing system. This 8-K contains no details about the content of that filing, making it a procedural cross-reference with no disclosed material business impact.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 4, 2026 · How we verify